Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12035659 | 0.90 | TSHR (0.55) | TSHRRAB9ANPC1TDP1ALDH1A1 | |
| SCHEMBL28414452 | 0.83 | ALDH1A1 (0.60) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL13445453 | 0.83 | NPC1 (0.60) | TSHRRAB9ANPC1LMNATDP1 | |
| SCHEMBL9505665 | 0.82 | TDP1 (0.57) | TSHRRAB9ANPC1LMNATDP1 | |
| SCHEMBL8773117 | 0.82 | TDP1 (0.57) | TSHRRAB9ANPC1LMNATDP1 | |
| SCHEMBL23754766 | 0.81 | LMNA (0.58) | TSHRRAB9ANPC1LMNATDP1 | |
| SCHEMBL2348902 | 0.81 | LMNA (0.62) | TSHRRAB9ANPC1LMNAALDH1A1 | |
| SCHEMBL3973277 | 0.81 | LMNA (0.53) | TSHRRAB9ANPC1LMNATDP1 | |
| SCHEMBL2691863 | 0.80 | MAPK1 (0.53) | TSHRRAB9ANPC1LMNATDP1 | |
| SCHEMBL20168310 | 0.80 | TSHR (0.54) | TSHRRAB9ANPC1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349624-A1 | PRO-DRUG FORMING COMPOUNDS | EVESTRA, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349624-A1 | PRO-DRUG FORMING COMPOUNDS | EVESTRA, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9745338-B2 | Pro-drug forming compounds | EVESTRA, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745338-B2 | Pro-drug forming compounds | EVESTRA, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| WO-2015006691-A1 | PRO-DRUG FORMING COMPOUNDS | EVESTRA, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| CN-1633434-A | Imidazo [1, 2-a ] pyridine derivatives | DAIICHI SEIYAKU CO (JP) | 2005-06-29 | — | — | CN | disclosed |
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1479681-A1 | IMIDAZO(1,2-a)PYRIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
| WO-2004007417-A1 | ENZYME INHIBITORS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2004-01-22 | — | — | WO | disclosed |
| EP-0198397-B1 | METHOD OF PRODUCING L-PHENYLALANINE | KURARAY CO., LTD. (JP) | 1993-01-07 | — | — | EP | disclosed |
| US-4743547-A | PURITY, ENZYME HYDROLYSIS | KURARAY CO., LTD. (JP) | 1988-05-10 | — | — | US | disclosed |
| EP-0198397-A2 | Method of producing L-phenylalanine | KURARAY CO., LTD. (JP) | 1986-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349624-A1 | PRO-DRUG FORMING COMPOUNDS | SUCNR1, FURIN, PROKR2 | TSHR 628/4885RAB9A 563/4885NPC1 2114/4885 |
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | MANBA, MAN2B1, ERG28 | TSHR 4471/4885RAB9A 2347/4885NPC1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.